INCY ▲ +0.2% - Incyte Corporation
$INCY Q3 2026: Total revenue $1.56b, up 14% YoY Net sales $1.32b, up 14% YoY Jakafi $827m, up 4% Opzelura $255m, up 36% Hematology/Oncology $235m, up 38% Raising FY26 guidance across portfolio
29-OCT-2026 07:07 AM ET
Share this post
More filings for $INCY
INCY ▼ -2.8% - Incyte CorporationNov 16, 2026INCY - Incyte Corporation - SEC Filing Update (12-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 12, 2026INCY ▼ -1.7% - Incyte CorporationOct 26, 2026
View full $INCY filing history →💬 Comments
Loading comments…
Leave a comment
